LEADER 06247nam 2201573z- 450 001 9910580215803321 005 20231214133001.0 035 $a(CKB)5690000000011929 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87543 035 $a(EXLCZ)995690000000011929 100 $a20202207d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (296 p.) 311 $a3-0365-4490-9 311 $a3-0365-4489-5 330 $aNanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations. 517 $aNanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease 606 $aTechnology: general issues$2bicssc 606 $aHistory of engineering & technology$2bicssc 606 $aMaterials science$2bicssc 610 $apoly(lactic-co-glycolic acid) (PLGA) 610 $ablood?brain barrier (BBB) 610 $acurrent Good Manufacturing Practice (cGMP) 610 $aFood and Drug Administration (FDA) 610 $ananotechnology 610 $aPLGA nanoparticles 610 $aneurodegenerative diseases 610 $adrug delivery 610 $acentral nervous system 610 $aneuroprotective drugs 610 $afluorescent labeling 610 $aDiI 610 $acoumarin 6 610 $arhodamine 123 610 $aCy5.5 610 $aquantum yield 610 $abrightness 610 $astability of fluorescent label 610 $aconfocal microscopy 610 $aintracellular internalization 610 $ain vivo neuroimaging 610 $adouble-emulsion method 610 $adry powder inhalation 610 $aantigen release 610 $aporous PLGA particles 610 $amicrofluidics 610 $amethotrexate 610 $achitosan 610 $aPLA/PLGA 610 $asustained release 610 $amicro-implant 610 $aanimal model 610 $aminimally invasive 610 $adrug delivery system 610 $ananoparticles 610 $apoly (lactic-co-glycolic acid) (PLGA) 610 $amicrofluidic 610 $apharmacokinetics (PK) and biodistribution 610 $aatorvastatin calcium 610 $apoly(lactide-co-glycolide) 610 $apolymeric nanoparticles 610 $acarrageenan induced inflammation 610 $aanti-inflammatory 610 $aradiolabeled nanoparticles 610 $anuclear medicine 610 $aphotothermal therapy 610 $aphthalocyanine 610 $aSKOVip-kat 610 $aKatushka 610 $aTurboFP635 610 $aJO-4 610 $aPLGA 610 $aorthotopic tumors 610 $a3D culture 610 $aspheroids 610 $apoly(lactic-co-glycolic acid) 610 $ananomedicine 610 $ascale-up manufacturing 610 $aclinical translation 610 $ainline sonication 610 $atangential flow filtration 610 $alyophilization 610 $adownstream processing 610 $aH. pylori 610 $adesign of experiments 610 $apoly(lactic-co-glycolic) acid 610 $asize 610 $acancer 610 $achemoimmunotherapy 610 $aimmunogenic cell death 610 $aimmune checkpoint blockade 610 $aPNA5 glycopeptide 610 $amas receptor 610 $aangiotensin 610 $aPLGA diblock copolymer 610 $aester and acid-end capped 610 $adouble emulsion solvent evaporation 610 $abiocompatible 610 $abiodegradable 610 $acardiovascular 610 $ananoparticle 610 $asolid-state characterization 610 $ain vitro 610 $adrug release kinetics modeling 610 $aPEGylation 610 $aamine 610 $aemulsion 610 $apolyvinyl alcohol (PVA) 610 $aPluronic triblock copolymer 610 $atrehalose 610 $asucrose 610 $aIndomethacin 610 $asolvents 610 $astabilizers 610 $amorphology 610 $aparticle-size 610 $aencapsulation 610 $adrug release 610 $acytotoxicity 615 7$aTechnology: general issues 615 7$aHistory of engineering & technology 615 7$aMaterials science 700 $aTagit$b Oya$4edt$01313404 702 $aTagit$b Oya$4oth 906 $aBOOK 912 $a9910580215803321 996 $aNanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside$93031389 997 $aUNINA